GlassScriptPhysician profile
Amanda Carroll
NPI 1396079208
$55,109.87
in general payments reported to CMS, 2019-2025
20 companies · $9,717 in 2025
The $9,717 reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,549 · 2020: $1,554 · 2021: $7,325 · 2022: $11K · 2023: $14K · 2024: $9,366 · 2025: $9,717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $32K · Food and Beverage: $1,723.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $31,609.20 |
| Food and Beverage | $1,723.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $50,630.78 | 2021-2025 | Nexplanon |
| Merck Sharp & Dohme LLC | $2,968.58 | 2019-2021 | |
| Abbvie INC. | $536.15 | 2019-2025 | Lo Loestrin Fe, Vraylar |
| Astellas Pharma US INC | $150.67 | 2024-2025 | Veozah |
| Exeltis, USA INC. | $134.50 | 2021-2025 | Slynd |
| Mayne Pharma Commercial LLC | $104.85 | 2021-2025 | |
| Myovant Sciences INC. | $83.73 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $82.08 | 2019-2025 | |
| Hologic Sales and Service, LLC | $49.39 | 2025 | Aptima, Thinprep 2000 Processor, Third Wave |
| Avion Pharmaceuticals | $47.55 | 2021-2022 | |
| Minerva Surgical, INC | $43.57 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $42.25 | 2024 | Myfembree |
| Therapeuticsmd, INC. | $41.22 | 2021-2022 | |
| Novo Nordisk INC | $38.22 | 2025 | |
| Mylan Pharmaceuticals INC. | $34.23 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $32.98 | 2024-2025 | |
| Daiichi Sankyo INC. | $27.09 | 2022 | |
| Covidien LP | $26.20 | 2019 | |
| Evofem Biosciences, INC. | $18.05 | 2021 | |
| Lilly USA, LLC | $17.78 | 2024 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Carroll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.